Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related ...

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating multiple myeloma.

and Pfizer’s Elrexfio (elranatamab), which have both been cleared by the FDA for relapsed or refractory multiple myeloma. The top-line efficacy data with Regeneron’s drug looks a little ...

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our ... with relapsed/refractory (“R/R”) multiple myeloma (“MM”); the likelihood, timing ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

The Food and Drug Administration is reviewing the biologics licence application for the antibody in the US, with a decision expected by 10 July 2025. Regeneron Pharmaceuticals president ...

Regeneron gets EU nod for multiple myeloma treatment Apr. 28, 2025 9:26 AM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock By: Nilanjana Basu , SA News Editor 1 Comment Play ( <1min ) ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab) has been granted conditional marketing approval by the European Commission (EC) to treat relapsed and refractory (R/R) multiple myeloma (MM).

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary ... or bortezomib in patients with relapsed/refractory ("R/R”) multiple myeloma ("MM”); ...